Urticarial vasculitis
(Redirected from Hypocomplementemic urticarial vasculitis syndrome)
Urticarial Vasculitis[edit | edit source]
Urticarial vasculitis is a rare form of vasculitis characterized by the presence of urticarial lesions that are associated with histological evidence of leukocytoclastic vasculitis. Unlike typical urticaria, the lesions in urticarial vasculitis are often painful, last longer than 24 hours, and may leave residual hyperpigmentation.
Pathophysiology[edit | edit source]
Urticarial vasculitis is associated with the activation of the complement system, particularly the classical pathway. The complement pathway is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells. In urticarial vasculitis, the activation of the complement system leads to inflammation and damage to the small blood vessels in the skin.
Clinical Features[edit | edit source]
Patients with urticarial vasculitis typically present with:
- Urticarial lesions that are painful or burning rather than itchy.
- Lesions that persist for more than 24 hours.
- Possible systemic symptoms such as fever, arthralgia, and abdominal pain.
- Residual hyperpigmentation or purpura after the lesions resolve.
Diagnosis[edit | edit source]
The diagnosis of urticarial vasculitis is confirmed by a skin biopsy showing leukocytoclastic vasculitis. Laboratory tests may reveal low levels of complement components, such as C3 and C4, indicating complement consumption.
Treatment[edit | edit source]
Treatment of urticarial vasculitis depends on the severity of the disease and the presence of systemic involvement. Options include:
- Antihistamines for symptomatic relief.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) for pain and inflammation.
- Corticosteroids for more severe cases.
- Immunosuppressive agents such as azathioprine or cyclophosphamide for refractory cases.
Prognosis[edit | edit source]
The prognosis of urticarial vasculitis varies. Some patients experience a self-limited course, while others may have chronic or recurrent disease. The presence of systemic involvement can affect the overall prognosis.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD